Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

Short seller Culper Research has accused Praxis Precision Medicines of engineering a positive Phase 3 readout for ulixacaltamide by changing the primary endpoint late without FDA sign‑off, using optimistic imputations for 36% of treated patients who discontinued, and applying inconsistent statistical methods—allegations it says could jeopardize FDA approval ahead of a pre‑NDA meeting. The report highlights red flags including a Phase 2 failure, a March 2025 independent data monitoring committee recommendation to stop Essential3 for futility (which Praxis ignored), three prior mechanism failures, and the asset’s $1 million 2018 acquisition, arguing these factors undercut sell‑side assumptions that value the drug at about $3 billion and underpin most of Praxis’s ~$4.5 billion market cap. Praxis raised $567 million after announcing the Phase 3 topline results, but shares dropped roughly 9.1% on the Culper report, which warns of material downside if regulators or independent experts agree with its conclusions.

Analysis

Culper Research alleges Praxis engineered a positive Phase 3 Essential3 readout for ulixacaltamide by changing the primary endpoint late without FDA sign‑off, imputing optimistic outcomes for the 36% of treated patients who discontinued, and applying statistical methods that the short seller says contradict cited research; those claims are supported in the report by consultations with former Praxis directors, a biostatistician and former FDA officials. The article notes the program has prior adverse signals: ulixacaltamide failed the Phase 2 Essential1 study, an independent data monitoring committee recommended halting Essential3 for futility in March 2025 (which Praxis overrode), and three prior compounds with similar biology previously failed in ET programs. Praxis’ market narrative is concentrated in this asset: sell‑side models cited in the article assign roughly an $3 billion valuation to ulixacaltamide and analysts have put approval odds near 80%, underpinning most of Praxis’ ~ $4.5 billion market capitalization; Praxis raised $567 million immediately after releasing the Phase 3 topline. Market reaction has been negative (shares down ~9.1% to $172.10 on publication) and the short report frames a clear binary catalytic risk ahead of Praxis’ late‑year pre‑NDA meeting with the FDA, implying meaningful downside if regulators or independent reviewers find the alleged methodological issues persuasive.

Key Decisions for Investors

• Reduce or hedge PRAX exposure until independent review or FDA feedback on endpoint changes and imputation methods are available, given the binary regulatory risk highlighted by Culper Research and the stock's concentration in a single asset
• Require release or independent access to patient‑level data, DMC minutes and trial protocol amendment history before re‑rating the asset; monitor the pre‑NDA meeting timeline and any FDA statements as primary catalysts
• If maintaining a long position, consider buying downside protection (puts or collars) sized to the position because a negative regulatory outcome could trigger a large re‑rating despite the recent $567 million capital raise
• Recalibrate valuation models to stress‑test scenarios where approval odds are materially below sell‑side estimates (eg. remove or sharply discount the $3 billion asset valuation) and treat current analyst probabilities as conditional rather than definitive